BACKGROUND/AIM: The performance of the circulating tumor markers carbohydrate antigen 19-9 (CA19-9), matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase 1 (TIMP-1) were evaluated separately and in combination for their potential value in detecting pancreatic ductal adenocarcinoma. PATIENTS AND METHODS: The patients had symptoms of pancreatic cancer. The discriminative strength of MMP-9 and TIMP-1 were compared to that of CA19-9 using receiver operating characteristics curves, area under the curves (AUC), specificity and sensitivity. RESULTS: The sensitivities of MMP-9, TIMP-1 and CA19-9 in detecting pancreatic ductal adenocarcinoma were 58.82%, 47.1% and 86%, respectively, with specificities of 34.6%, 69.2% and 73%. The AUCs of MMP-9, TIMP-1 and CA19-9 were 0.50, 0.64 and 0.84, respectively. Combining the three markers did not significantly improve detection of pancreatic ductal adenocarcinoma compared to CA19-9 used alone. CONCLUSION: Circulating MMP-9 and TIMP-1 were inferior to CA19-9 as markers for detecting pancreatic ductal adenocarcinoma and did not improve the diagnostic accuracy when combined with CA19-9.
BACKGROUND/AIM: The performance of the circulating tumor markers carbohydrate antigen 19-9 (CA19-9), matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase 1 (TIMP-1) were evaluated separately and in combination for their potential value in detecting pancreatic ductal adenocarcinoma. PATIENTS AND METHODS: The patients had symptoms of pancreatic cancer. The discriminative strength of MMP-9 and TIMP-1 were compared to that of CA19-9 using receiver operating characteristics curves, area under the curves (AUC), specificity and sensitivity. RESULTS: The sensitivities of MMP-9, TIMP-1 and CA19-9 in detecting pancreatic ductal adenocarcinoma were 58.82%, 47.1% and 86%, respectively, with specificities of 34.6%, 69.2% and 73%. The AUCs of MMP-9, TIMP-1 and CA19-9 were 0.50, 0.64 and 0.84, respectively. Combining the three markers did not significantly improve detection of pancreatic ductal adenocarcinoma compared to CA19-9 used alone. CONCLUSION: Circulating MMP-9 and TIMP-1 were inferior to CA19-9 as markers for detecting pancreatic ductal adenocarcinoma and did not improve the diagnostic accuracy when combined with CA19-9.
Authors: Randall E Brand; Brian M Nolen; Herbert J Zeh; Peter J Allen; Mohamad A Eloubeidi; Michael Goldberg; Eric Elton; Juan P Arnoletti; John D Christein; Selwyn M Vickers; Christopher J Langmead; Douglas P Landsittel; David C Whitcomb; William E Grizzle; Anna E Lokshin Journal: Clin Cancer Res Date: 2011-02-15 Impact factor: 12.531
Authors: László Herszényi; István Hritz; Gábor Lakatos; Mária Zsófia Varga; Zsolt Tulassay Journal: Int J Mol Sci Date: 2012-10-16 Impact factor: 5.923